Navigation Links
Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Date:3/9/2009

TUSTIN, Calif., March 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 am EDT at the Boston Marriott Copley Place.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at www.peregrineinc.com. The archived replay will be available for approximately 30 days following the presentation.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                 Media
    info@peregrineinc.com                     Barbara Lindheim
    (800) 987-8256                            (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
4. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
5. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
8. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
11. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 27, 2016 , ... The Pittcon Organizing Committee is pleased to announce that ... volunteer member of Committee since 1987. Since then, he has served in a number ... was chairman for both the program and exposition committees. In his professional career, Dr. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... to announce the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton ... one of the founding commercial leaders responsible for the commercialization of multiple orphan ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Global ... the GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in ... Miami, where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression ...
(Date:4/26/2016)... Calif. (PRWEB) , ... April 27, 2016 , ... ... office of Lewis Roca Rothgerber Christie LLP as an associate in the firm’s ... U.S. and international electrical, mechanical and electromechanical patent applications. He has an electrical ...
Breaking Biology Technology:
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
Breaking Biology News(10 mins):